Betamethasone for Breathing Support in Premature Babies

This trial explores whether betamethasone, a steroid, can help extremely premature babies (born before 28 weeks) breathe easier and reduce the risk of long-term lung problems. The trial will assess if this medication enables babies to come off breathing machines safely without affecting growth or development. Babies in the study will receive standard NICU care, with only some receiving betamethasone based on specific treatment criteria. Families with babies born before 28 weeks and admitted to a participating NICU may consider this trial. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important findings.

The trial information does not specify whether you need to stop your baby's current medications. It mentions that all babies will receive standard NICU care, which usually includes continuing necessary medications.

Research has shown that betamethasone can aid in the lung development of preterm babies before birth. Studies indicate that babies receiving this steroid often require less breathing assistance after birth. However, some risks exist. For instance, certain studies found that babies exposed to betamethasone might experience low blood sugar after birth, a condition known as neonatal hypoglycemia. Doctors monitor this closely. Overall, betamethasone is usually well-tolerated, but weighing the potential benefits and risks is important.¹²³⁴⁵

Unlike the standard treatments for breathing support in premature babies, which usually involve mechanical ventilation or surfactant therapy, betamethasone works by reducing inflammation in the lungs. This steroid can potentially enhance lung function and decrease the need for invasive breathing support. Researchers are excited about betamethasone because it could offer a less invasive option, minimizing potential complications associated with other treatments. Additionally, its anti-inflammatory properties may improve overall outcomes for these vulnerable infants.

Studies have shown that betamethasone can greatly help extremely premature babies breathe better. Research indicates that it lowers the risk of chronic lung disease, common in these infants. In this trial, infants meeting clinical criteria will receive postnatal betamethasone. One study found that babies who received betamethasone were less likely to need breathing support soon after birth. Another study showed a 33% decrease in serious breathing problems with this steroid. Overall, betamethasone seems to support lung development, making it easier for babies to breathe independently.²⁶⁷⁸⁹